SCHEMBL5200476

SCHEMBL5200476

NC1CC=C(c2[c]nccc2)CC1

nearest known ligand 0.31

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
CCNT1 O60563 1/20 0.31
CDK9 P50750 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9318946 0.70 TDP1 (0.38)
SCHEMBL14336758 0.69 PLAU (0.41)
SCHEMBL4909130 0.66
SCHEMBL17548224 0.62 HTR2C (0.43)
SCHEMBL19808113 0.62 ESR2 (0.39) CCNT1CDK9
SCHEMBL5151774 0.62 SIGMAR1 (0.43)
SCHEMBL17729316 0.62 CHRM2 (0.36)
SCHEMBL22893013 0.62 PLAU (0.35) CCNT1CDK9
SCHEMBL17729281 0.61 CCNT1 (0.34) CCNT1CDK9
SCHEMBL24831847 0.60 CHRNB2 (0.38)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11858910-B2 Pyridinylmethylenepiperidine derivatives and uses thereof SUNSHINE LAKE PHARMA CO., LTD. (CN) 2024-01-02 US disclosed
US-20210188803-A1 PYRIDINYLMETHYLENEPIPERIDINE DERIVATIVES AND USES THEREOF SUNSHINE LAKE PHARMA CO., LTD. (CN) 2021-06-24 US disclosed
US-7312236-B2 Substituted (4-aminocyclohexen-1-yl)phenyl and (4-aminocyclohexen-1-yl)pyridinyl compounds as 5-HT1F agonists ELI LILLY AND COMPANY (US) 2007-12-25 US disclosed
US-7312236-B2 Substituted (4-aminocyclohexen-1-yl)phenyl and (4-aminocyclohexen-1-yl)pyridinyl compounds as 5-HT1F agonists ELI LILLY AND COMPANY (US) 2007-12-25 US disclosed
EP-1697305-B1 SUBSTITUTED (4-AMINOCYCLOHEXEN-1-YL)PHENYL AND (4-AMINOCYCLOHEXEN-1-YL)PYRIDINYL COMPOUNDS AS 5-HT1F AGONISTS LILLY CO ELI (US) 2007-08-15 EP disclosed
US-20070078169-A1 Substituted (4-aminocyclohexen-1-yl)phenyl and (4-aminocyclohexen-1-yl)pyridinyl compounds as 5-ht1f agonists ELI LILLY AND COPANY 2007-04-05 US disclosed
US-20070078169-A1 Substituted (4-aminocyclohexen-1-yl)phenyl and (4-aminocyclohexen-1-yl)pyridinyl compounds as 5-ht1f agonists ELI LILLY AND COPANY 2007-04-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070078169-A1 Substituted (4-aminocyclohexen-1-yl)phenyl and (4-aminocyclohexen-1-yl)pyridinyl compounds as 5-ht1f agonists HTR1F, HTR1A, HTR1E CCNT1 1423/4885CDK9 4416/4885
US-11858910-B2 Pyridinylmethylenepiperidine derivatives and uses thereof HTR1F, HTR1A, HTR5A CCNT1 2417/4885CDK9 2190/4885
US-20210188803-A1 PYRIDINYLMETHYLENEPIPERIDINE DERIVATIVES AND USES THEREOF HTR1F, HTR1A, HTR5A CCNT1 2417/4885CDK9 2190/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.